Bcl-2 family proteins serve as critical regulators of pathways involved in apoptosis, acting to either inhibit or promote cell death. Altered expression of these proteins occurs commonly in human cancers, contributing to neoplastic cell expansion by suppressing programmed cell death and extending tumor cell life span. Moreover, because chemotherapeutic drugs typically exert their cytotoxic actions by inducing apoptosis, the ultimate ecacy of most anticancer drugs can be heavily in¯uenced by the relative levels and state of activation of members of the Bcl-2 family. The question of how Bcl-2 family proteins function remains debatable, but new ®ndings are shaping our impressions of these multifunctional proteins and revealing the details of how these proteins participate in the regulation of cell life and death.
Introduction
One of these most prominent families of apoptosis regulators is represented by Bcl-2 and its homologs, of which there are at least 16 in humans (reviewed in Chao and Korsmeyer, 1998; Reed, 1994; Zamzami et al., 1998a) . The apoptosis-suppressing Bcl-2 gene was discovered as a proto-oncogene found at the breakpoints of t(14;18) chromosomal translocations in lowgrade B-cell lymphomas. These lymphomas represent quintessential examples of human malignancies in which the neoplastic cell expansion can be attributed primarily to failed programmed cell death rather than rapid cell division. Initial gene transfection studies of Bcl-2 demonstrated that over-production of the protein signi®cantly prolongs cell survival in the face of classical apoptotic stimuli, including lymphokine deprivation from factor-dependent hematopoietic cells, glucocorticoid treatment of thymocytes and lymphoid leukemia cells, g-irradiation of thymocytes, and NGF-deprivation from fetal sympathetic neurons (reviewed in Reed, 1994) . Conversely, antisensemediated suppression of Bcl-2 expression was demonstrated to induce or accelerate cell death (Reed et al., 1990) . It was thus that Bcl-2 emerged as the ®rst example of an intracellular apoptosis-suppresser and the ®rst identi®ed proto-oncogene which contributed to neoplasia through eects on cell life span regulation rather than cell division. Subsequent genetic studies of C. elegans mutants revealed an anti-apoptotic Bcl-2 homolog, CED-9, implying that Bcl-2 governs an evolutionarily conserved step in the programmed cell death machinery ± a hypothesis further supported by experiments in which human Bcl-2 was found to be capable of rescuing, at least partially, CED-9 de®cient worms (Hengartner and Horvitz, 1994a; Vaux et al., 1992) .
These early studies of Bcl-2 and its homologs created great interest among apoptosis researchers in understanding how the Bcl-2 protein performs its cytoprotective functions in cells. Despite over 10 years of eort, however, many issues remain unresolved regarding the biochemical mechanisms of Bcl-2 and its relatives.
Multiple mechanisms of action
Bcl-2 appears to defy the dictum:`One gene?One protein?One function.' Rather, Bcl-2 is a multifunctional protein. At least three general functions for Bcl-2 and some of its anti-apoptotic homologs such as Bcl-X L have been identi®ed: (a) Dimerization with other Bcl-2 family proteins; (b) binding to nonhomologous proteins; and (c) formation of ionchannels/pores (reviewed in Green and Reed, 1998; Reed, 1997a,b; Schendel et al., 1998; Vaux and Strasser, 1996; Zamzami et al., 1998a) . Each of these functions will be discussed here brie¯y. From the outset, any discussion of the functions of Bcl-2 family proteins must take into consideration their locations in cells. Bcl-2 and many of its homologs contain a stretch of hydrophobic amino-acids at their C-termini ( Figure  1 ) that result in post-translational insertion into intracellular membranes, primarily the outer mitochondrial membrane, nuclear envelope, and endoplasmic reticulum (ER) (Krajewski et al., 1993; Lithgow et al., 1994; Yang et al., 1995b; Zha et al., 1996b) .
Deadly liaisons: dimerization of Bcl-2 family proteins
A milestone in understanding how Bcl-2 functions came when it was discovered that Bcl-2 was capable of heterodimerizing with its pro-apoptotic relative Bax (Oltvai et al., 1993) . The hypothesis thus emerged that anti-apoptotic proteins such as Bcl-2 and pro-apoptotic proteins such as Bax do battle with each other by hand-to-hand combat, with the Bcl-2 : Bax ratio dictating the relative sensitivity or resistance of cells to a wide variety of apoptotic stimuli . However, it was unclear whether Bcl-2 operated as the eector protein responsible for ensuring survival, with Bax playing the role of transdominant inhibitor; or conversely, Bax functioning as an eector of death with Bcl-2 acting as its transdominant inhibitor. After multiple attempts to address this issue, probably the most reasonable conclusion is that both views are correct.
Bcl-2 and Bax appear to have intrinsic independent functions as eectors of survival and death, respectively. This view of separable, independent functions for Bcl-2 and Bax is supported by both biochemical and genetic arguments. The evidence, for example, includes investigations of mutants of Bcl-2 and Bax that are incapable of dimerizing but which nevertheless display antagonistic activity towards each other and remain capable of repressing or inducing cell death, respectively (Cheng et al., 1996; Simonian et al., 1996a,b; Tao et al., 1997; Wang et al., 1998; Zha and Reed, 1997) . Other support derives from experiments in which Bcl-2 or Bax were expressed in cellular contexts where either Bcl-2 homologs are absent altogether (yeast) or in which either Bcl-2 or Bax were selectively eliminated (knock-out mice) (Hanada et al., 1995; Ink et al., 1997; JuÈ rgensmeier et al., 1997; Kane et al., 1993; Knudson and Korsmeyer, 1997; Longo et al., 1997; Sato et al., 1994; Tao et al., 1997) . Under these conditions, Bcl-2 was found to be capable of prolonging cell survival even in the absence of Bax; and conversely, Bax was reported to promote cell death even without Bcl-2 present.
Though Bcl-2 and Bax may be capable of functioning independently, it is also clear that dimerization among Bcl-2 family members does provide an important mechanism for controlling their activity. Sequence comparisons of the Bcl-2 family members have revealed up to four conserved domains, called Bcl-2 Homology (BH) domains: BH1, BH2, BH3 and BH4 (Figure 1 ). Mutagenesis studies identi®ed a conserved domain, BH3, within several of the proapoptotic Bcl-2 family members which was shown to be critical for both dimerization with anti-apoptotic proteins such as Bcl-2 or Bcl-X L and for induction of apoptosis (reviewed in Kelekar and Thompson, 1998) . Of note, several pro-apoptotic members of the Bcl-2 family protein contain the BH3 domain as their only apparent similarity with other members of the family, constituting the so-called`BH3-only' branch of the Bcl-2 family (Figure 1 ). Most of these proteins, including Bik/Nbk, Hrk/DP5, Bim/Bad, Blk, and Bad, operate as Figure 1 The Bcl-2 family. The topologies of several of the Bcl-2 family proteins are depicted, illustrating the BH1, BH2, BH3 and BH4 domains, as well as the transmembrane (TM) domains. Some of these proteins contain BH3-like (BH3-L) domains. The Bcl-X L and Bcl-X S protein arise through alternative mRNA slicing mechanisms from the same gene (Boise et al., 1993) . Two xenopus Bcl-2 homologs have also been described (Cruz-Reyes and Tata, 1995) . The viral homologs of Bcl-2 are not shown trans-dominant inhibitors of anti-apoptotic proteins such as Bcl-2 and Bcl-X L , relying exclusively on dimerization for their bioactivities. These proteins do not generally dimerize with pro-apoptotic members of the Bcl-2 family and cannot homodimerize. An analogous situation occurs in the nematode Caenorhabiditis elegans, an organism in which the genetics of programmed cell death has been extensively studied. In the worm, the Bcl-2 homolog CED-9 is inhibited by interactions with a BH3-only protein called EGL-1, at least in certain types of cells (Conradt and Horvitz, 1998) . Deletion of the BH3 domains from the BH3-only proteins uniformly abolishes their functions as inducers of cell death and prevents their binding to anti-apoptotic proteins such as Bcl-2, Bcl-X L and CED-9. Thus, dimerization and function are inextricably linked in these proteins.
The structural basis for dimerization among Bcl-2 family proteins has been elucidated using a combination of X-ray crystallography and NMR methods (Muchmore et al., 1996; Sattler et al., 1997) . The structure of the Bcl-X L protein consists of seven amphipathic a-helices joined by¯exible loops. The BH4 and BH3 domains correspond to the ®rst and second amphipathic a-helices in these proteins, as predicted from the 3-dimensional structure of Bcl-X L (Muchmore et al., 1996) . The BH1 domain coincides with a loop located upstream of the ®fth a-helix in Bcl-X L and extends partially into this a-helix, whereas the BH2 domain has been assigned to the latter portion of the 6th a-helix and loop which follows thereafter. The BH1, BH2 and BH3 domains in combination form the borders of a hydrophobic pocket located on the surface of the Bcl-X L protein. Certain mutations that aect residues lining this pocket, such as Gly145Ala in the BH1 domain of human (hu) Bcl-2 protein and Gly159 Ala in the BH1 domain of hu-Bcl-X L have been shown to abrogate their ability to dimerize with Bax (Sedlak et al., 1995; Yin et al., 1994) . Thus, this surface pocket appears to function analogous to a receptor, binding epitopes located on partner proteins that dimerize with Bcl-2 and Bcl-X L . Through a combination of deletional and mutagenesis studies (Boyd et al., 1995; Chittenden et al., 1995; Inohara et al., 1997; Wang et al., 1996b; Zha et al., 1996a,b) , peptide competition assays (Diaz et al., 1997) , and NMR-based structural analyses (Sattler et al., 1997) , it has been determined that the BH3 domain represents the counter-structure on dimerizing Bcl-2 family proteins which inserts (similar to a peptide ligand) into the surface pocket created by the combination of BH1, BH2, and BH3. Moreover, it is the hydrophobic face of the BH3 a-helix that is required for binding to this pocket (Kelekar et al., 1997; Sattler et al., 1997; Wang et al., 1998) . This ®nding implies that at least some Bcl-2 family proteins exist in two conformations: one in which the protein creates a receptor-like pocket and the other in which the amphipathic a-helix that comprises BH3 rotates outward to expose its hydrophobic surface so that it can bury this side of the a-helix into the receptor-like crevice on dimerization partner proteins (Sattler et al., 1997) .
The dimerization properties and functional characteristics of the BH3-only subgroup of pro-apoptotic Bcl-2 family proteins can be contrasted with proapoptotic proteins such as Bax, Bak, and Bok/Mtd which share greater amino acid sequence identity with Bcl-2. Molecular modeling studies suggest that proteins such as Bax probably assume the same general structure as Bcl-X L . Unlike BH3-only proteins, Bax and Bak can homodimerize with themselves, in addition to heterodimerizing with proteins such as Bcl-2, Bcl-X L , or Mcl-1. Currently, the preponderance of data available from structurefunction analysis of Bax and its close relatives suggest that these proteins possess two potentially independent mechanisms for promoting cell death. One mechanism relies upon the BH3 domain as a tool for suppressing the functions of speci®c anti-apoptotic Bcl-2 family members through dimerization, similar to BH3-only proteins. The other is an intrinsic, heterodimerizationindependent function, probably related to the ability of these proteins to insert into membranes as discussed below (reviewed in Kelekar and Thompson, 1998; Reed et al., 1998; Schendel et al., 1998) . Analogous to the BH3-only proteins, over-expression of fragments of Bax or Bak which encompass little more than the BH3 domain have been shown to be sucient for binding to Bcl-2 or Bcl-X L and inducing apoptosis in mammalian cells Simonen et al., 1997) and in cell-free systems (Cosulich et al., 1997) . In addition, substituting the BH3 domain of Bcl-2 for that of Bax has been reported to convert Bcl-2 from a protector to a killer protein (Hunter and Parslow, 1996) . However, consistent with the idea of an additional BH3-independent mechanism for cell death induction, some BH3 domain mutants of Bax that fail to bind Bcl-2 are nevertheless still capable of inducing apoptosis and are still suppressible by Bcl-2 or Bcl-X L , despite their apparent inability to dimerize with these proteins (Simonian et al., 1996b; Wang et al., 1998; Zha and Reed, 1997) . This apparent redundancy in the mechanisms by which Bax kills cells creates difficulties in attempting to dissect which of these routes is quantatively more important in various cellular contexts.
Hints of another BH3-independent mechanism for induction of apoptosis by Bcl-2 family members have come from structure-function analysis of the Nip3 and Nix (BNIP3L) proteins Matsushima et al., 1997; Yasuda et al., 1998) . Nip3 was ®rst identi®ed by virtue of its ability to bind the adenovirus Bcl-2 homolog, E1b-19K (Boyd et al., 1993) . Nip3 contains a BH3-like domain and induces apoptosis when over-expressed in cells, via a pathway which is at least partially suppressible by Bcl-2 Yasuda et al., 1998) . Recently, a close homolog of Nip3 was identi®ed, which is known as Nix or BNIP3L (Chen et al., 1998a; Matsushima et al., 1997) . Nip3 and Nix contain a BH3-like domain, as well as a C-terminal membrane-anchoring domain that targets them to mitochondria, similar to many other Bcl-2 family members. The membrane-targeting domain appears to be essential for the proapoptotic function of Nip3. In contrast, removal of the BH3 domain destroys binding to Bcl-2 and reduces but does not abolish Nip3's pro-apoptotic activity. Thus, Nip3 and presumably Nix may exert proapoptotic functions independently of BH3-mediated dimerization with Bcl-2 or other anti-apoptotic Bcl-2 family proteins.
One caveat about BH3-independent function of proapoptotic Bcl-2 family proteins, however, is that dimerization is typically assayed in solution, by in vitro binding assays, co-immunoprecipitation from detergent solubilized cells, or yeast two-hybrid assays using proteins lacking the C-terminal membrane-anchoring domains. It remains possible that some Bcl-2 family proteins such as Bax and Nip3 do retain the ability to interact with anti-apoptotic proteins such as Bcl-2 and Bcl-X L in membranes, despite deletions or mutations in their BH3 regions. Indeed, recent chemical crosslinking studies suggest this may be true at least in the case of Bax .
Running around with a Bad crowd: dynamic movements of Bcl-2 family proteins Most Bcl-2 family members contain a C-terminal hydrophobic stretch of amino acids that anchors them in membranes (Figure 1 ), predominantly the outer mitochondrial membrane, endoplasmic reticulum and nuclear envelope. However, at least two pro-apoptotic BH3-only proteins, Bad and Bid, lack membraneanchoring domains (Wang et al., 1996b; Yang et al., 1995a) . The locations of these proteins in cells is dynamically controlled by their association/dissociation with other Bcl-2 family proteins, resulting in a regulated translocation between the cytosol and the surface of membranous organelles where other Bcl-2 family proteins reside. The Bad protein, for example, dimerizes with Bcl-X L and to some extent with Bcl-2, thereby promoting apoptosis. Phosphorylation of the Bad protein by a variety of kinases, including Akt/Pkb, and Raf-1 can prevent Bad from interacting with Bcl-X L , thus ablating its pro-apoptotic function (BlumeJensen et al., 1998; Datta et al., 1997; del Peso et al., 1997; Wang et al., 1996a; Zha et al., 1996c) . This regulation of Bad protein activity by phosphorylation appears to represent one of the mechanisms by which growth factor receptors convey signals for cell survival. Admittedly, however, this is not the only mechanism used by growth factor and neutrophic factor receptors for maintaining cell survival, since Bad is not expressed in all types of cells and since other potentially relevant substrates, including caspase-family cell death proteases, have been identi®ed for some of these kinases such as Akt (Cardone et al., 1998) .
The Bid protein also exhibits dynamic movements from cytosol to membranes. The post-translational modication that controls Bid translocation however is proteolysis rather than phosphorylation. Bid can be cleaved by caspase-8, the pinnical protease in the Fas/ TNF-pathway for apoptosis (for reviews see Salvesen and Dixit, 1997a; Wallach et al., 1997; Yuan, 1997) . Upon removal of its N-terminus, Bid then translocates to the surface of mitochondria, apparently dimerizing with Bcl-2 family proteins via its BH3 domain Luo et al., 1998) . Exactly how cleavage activates Bid remains unclear. Possibly it exposes the hydrophobic face of the BH3 a-helix so that it is available for dimerization, though alternative mechanisms have not been excluded. Moreover, caspaseindependent mechanisms for Bid translocation to membranes and dimerization with Bcl-2 family members may also exist. Interestingly, mutagenesis studies of the BH3 domain of Bid suggest that its binding to Bax rather than Bcl-2 or Bcl-X L is critical for its pro-apoptotic function (Wang et al., 1996b) . If true, then this observation raises the possibility that BH3-only proteins may function either as activators of Bax or as inhibitors of Bcl-2/Bcl-X L . The implications for cancer therapy are obvious: Design BH3-mimicking compounds that bind to and suppress anti-apoptotic proteins such as Bcl-2 and Bcl-X L (Cosulich et al., 1997) or alternatively that associate with and activate pro-apoptotic proteins such as Bax and Bak.
Sex with multiple partners: interactions of Bcl-2 family proteins with other proteins.
To date, Bcl-2 or Bcl-X L has been reported to interact with (or at least co-immunoprecipitate with) a wide variety of seemingly unrelated proteins, including: (i) the caspase-activating CED-4 homolog Apaf-1 Pan et al., 1998) ; (ii) the caspase-binding, Death Eector Domain (DED)-containing proteins Bap31 and MRIT (Flip/Flame/Cash/I-Flice/Casper/ Clarp) (Han et al., 1997; Ng et al., 1997) ; (iii) the protein kinase Raf-1 ; (iv) the GTPase R-Ras (and possibly H-Ras) (FernandezSarbia and Bischo, 1993) ; (v) the Ca 2+ -activated phosphatase Calcineurin (Shibasaki et al., 1997) ; (vi) the Hsp70/Hsc70 molecular chaperone regulator BAG-1 (Takayama et al., 1995) ; (vii) the p53 binding protein 53BP-2 (Naumovski and Cleary, 1996) ; (ix) a Prion protein (Kurschner and Morgan, 1995) ; (x) the multiple membrane spanning protein BI-1 (Xu and Reed, 1998) ; (xi) the spinal muscular atrophy protein SMN (Iwahashi et al., 1997) ; and (xii) the Adenine Nucleotide Translocator (ANT) of the mitochondrial inner membrane . In most cases where interrogated, thus far, dimerization of Bcl-2 or Bcl-X L with pro-apoptotic proteins such as Bax, Bad, or Bik disrupts interactions with other proteins, implying either that the same hydrophobic pocket implicated in dimerization of Bcl-2 family proteins is involved, or that dimerization induces conformational changes in Bcl-2/Bcl-X L that trigger release of these heterologous proteins. The BH4 domains of Bcl-2 and Bcl-X L appear to be required for several of these protein interactions, perhaps explaining why the proteins listed above generally do not bind to Bax or Bak (Figure 1 ) and suggesting that there may be more to the story than the BH3-binding pocket. It is tempting to speculate that these interactions of Bcl-2 or Bcl-X L with other proteins may account for their cytoprotective eects in the settings of Ca 2+ overload (Calcineurin), p53 induction (53BP-2); heat shock (BAG-1), and exposure to mitochondrial poisons (ANT). Though formal proof of this is lacking, Bcl-2 nevertheless does exhibit some interesting eects that can potentially be dissociated from cell death control and that may be linked directly to its interactions with these unrelated proteins, including preventing Calcineurin-mediated dephosphorylation and activation of the transcription factor NF-AT (Shibasaki et al., 1997) , blocking transcriptional repression by p53 (Sabbatini et al., 1995; Shen and Shenk, 1994) and targeting Raf-1 as well as BAG-1/Hsc70 complexes to mitochondria (Takayama et al., 1998; Wang et al., 1996a) . Bcl-2, Bcl-X L , and Bcl-W also have eects on cell proliferation that can be dissociated from their anti-apoptotic functions, a topic which will not be discussed here (Borner, 1996; Huang et al., 1997) . Taken together, therefore, these observations provide further support for the concept of Bcl-2 family proteins as multifunctional molecules.
Arguably, of all the proteins with which Bcl-2 and Bcl-X L can potentially interact, those directly linked to caspase activation seem likely to be among the most important. Strong genetic evidence from C. elegans implies a critical role for CED-9 interactions with CED-4 (Hengartner and Horvitz, 1994b) , a caspaseactivating protein which contains a CARD (Caspase Recruitment Domain) domain and putative ATPbinding P-loop (Chinnaiyan et al., 1997; Irmler et al., 1997) . Moreover, physical interactions between CED-9 and CED-4 have been demonstrated, and correlated with CED-9's ability to suppress CED-4 mediated activation of caspases (Chinnaiyan et al., 1997; Irmler et al., 1997; Seshagiri and Miller, 1997; Spector et al., 1997; Wu et al., 1997a,b) . In addition, dimerization of the BH3-only protein EGL-1 with CED-9 reportedly displaces CED-4, freeing it to activate caspases (del Peso et al., 1998).
The only CED-4 homolog thus far recognized in vertebrate animals is Apaf-1 (Zou et al., 1997) , though recent results from Apaf-1 knock-out mice imply the possible existence of others (Cecconi et al., 1998; Yoshida et al., 1998) . Apaf-1 contains a CED-4-like domain but unlike CED-4 is not constitutively active. Rather, Apaf-1 lies in a dormant state until supplied with dATP (or ATP) and another critical protein, cytochrome c, which is released from mitochondria during apoptosis (reviewed in Green and Reed, 1998; Reed, 1997a) . Once activated by cytochrome c and dATP/ATP, Apaf-1 forms complexes with pro-caspase-9 (Li et al., 1997b) , inducing caspase-9 activation. Caspase-9 then cleaves and activates downstream caspases, resulting in apoptosis.
Bcl-X L has been reported to bind Apaf-1, interacting with the CED-4-like region in this protein (Hu et al., 1997; Pan et al., 1998) . How this binding of Bcl-X L to Apaf-1 aects apoptosis, however, remains obscure. In some experimental systems, Bcl-X L apparently causes displacement of pro-caspase-9 from Apaf-1. In others, a terinary complex containing Bcl-X L , Apaf-1, and pro-caspase-9 reportedly can be detected. Formal proof that Bcl-X L is capable of inhibiting Apaf-1-mediated processing and activation of caspase-9 is lacking, though correlative evidence from cell transfection studies does exist in which Apaf-1 mutants were employed that lack a C-terminal negative regulatory domain . However, addition of large amounts of recombinant Bcl-X L or Bcl-2 protein to cytosolic extracts fails to interfere with Apaf-1 under conditions in which addition of cytochrome c can be used to trigger Apaf-1 activation and processing of pro-caspase-9 . Moreover, Bcl-2 either fails to bind Apaf-1 or does so very weakly, implying that Apaf-1 binding is not essential for Bcl-2's cytoprotective function. Interestingly, however, over-expression of Bcl-2 or Bcl-X L has been reported to delay apoptosis induced by microinjection or electroporation of cytochrome c in some types of cells (Zhivotovsky et al., 1998) , but not others (Garland and Rudin, 1998; Li et al., 1997a) , suggesting that Bcl-2 block apoptosis at the level of or downstream of Apaf-1 activation in some cellular contexts (reviewed in Hengartner, 1998) .
Additional evidence that Bcl-2 family proteins can regulate Apaf-1 come from the discovery of a new family member, Diva . The Diva protein contains BH1, BH2, BH4 and a BH3-like domain (Figure 1 ). Diva is a pro-apoptotic protein that reportedly forms complexes with Apaf-1, displacing Bcl-X L . The BH3 domain of Diva is not required for Apaf-1 binding or apoptosis; and Diva does not heterodimerize with Bcl-2, Bcl-X L or several cellular anti-apoptotic Bcl-2 family proteins. However, the Bcl-2 homolog, Kbcl-2, of the Kaposi's sarcoma-associated herpesvirus does bind and inhibits Diva-induced apoptosis . The implication is that Bcl-X L and Diva compete for binding to Apaf-1, with Bcl-X L presumably inhibiting and Diva enabling Apaf-1-induced activation of caspases. The adenovirus Bcl-2 homolog E1b-19K also may bind and interfere with Apaf-1 (Han et al., 1998) , providing another example in which a Bcl-2 family member apparently modulates this caspase-activating protein. Unless cytochrome c-independent pathways for Apaf-1 activation are uncovered, presumably these observations are limited to post-mitochondrial steps in apoptotic pathways where death signals have already triggered release of this cofactor required for Apaf-1 activation. The possibility exists however that other CED-4/Apaf-1 homologs will eventually be discovered that do not require cytochrome c for their activation.
Shot full of holes: Bcl-2 family proteins as pore-forming proteins
The ®rst suspicion that some Bcl-2 family proteins might be capable of forming pores or ion-channels in membranes came with the determination of the 3 dimensional structure of Bcl-X L (Muchmore et al., 1996) , revealing striking similarity to the pore forming domains of some types of bacterial toxins, e.g., diphtheria toxin (DT) and the colicins. The structures of DT, colicins, and Bcl-X L contain a pair of core hydrophobic helices that are long enough to penetrate the lipid bilayer and which are shielded from the aqueous environment by the other ®ve to seven amphipathic helices that orient their hydrophobic surfaces towards the central core helices and their hydrophilic surfaces outward. Studies of the bacterial toxins suggest that under conditions of a voltage gradient and low pH, the central hydrophobic helices insert through the lipid bilayer with the surrounding amphipathic helices folding up analogous to the opening of an umbrella (Cramer et al., 1992; Duche et al., 1996; Merrill et al., 1990; Parker et al., 1992; Shin et al., 1993) . In the case of colicins, additional ahelices subsequently also insert into membranes. Molecular modeling studies suggest that anti-apoptotic proteins such as Bcl-2 and some types of proapoptotic proteins such as Bax share the same fold with Bcl-X L .
As predicted by their structures, Bcl-2, Bcl-X L , and Bax have been shown to form ion-channels at least in vitro when added to synthetic membranes under conditions previously shown to be conducive for channel formation by DT and the bacterial colicins (Antonsson et al., 1997; Minn et al., 1997; Schendel et al., 1997; Schlesinger et al., 1997) . The relative conductances, ion-selectivities and dynamic characteristics of the channels formed by Bcl-2, Bcl-X L , and Bax appear to dier. Though far more work needs to be done, the gen-eral suggestion is that the cytoprotective proteins Bcl-2 and Bcl-X L tend to form small channels that assume a mostly closed conformation, preferring cations, whereas the pro-apoptotic protein Bax tends to form larger channels, which assume a mostly open conformation and prefer anions (reviewed in Schendel et al., 1998) . The structural basis for these dierences can presumably be attributed at least in part to dierences in the charges of the amino acid residues predicted to line the aqueous lumen of channels created by the putative pore-forming ®fth and sixth a-helices, but many issues remain unresolved, including the questions of precisely which a-helices insert into membranes and the stoichiometry of membraneinserted molecules which hypothetically might oligomerize to form large channels. Also unclear is how channel formation relates to the mutual anta-gonism displayed by anti-apoptotic proteins such as Bcl-2 and proapoptotic proteins such as Bax. In this regard, evidence has been obtained that under some in vitro conditions, Bcl-2 can prevent channel formation by Bax (Antonsson et al., 1997) , but this observation has not been transferable to other assays . Indeed, the intrinsic channel activities of Bcl-2 family proteins may have little relevance to their mechanism of action. Instead, inactions with other proteins in mem-branes may be the key to understanding how they function.
Though no direct evidence thus far been presented that Bcl-2 family proteins can form channels in vivo, evidence is amassing to suggest that proteins such as Bax do insert into membranes and exist in two conformational states that may represent active and latent versions of the protein. For example, in at least some types of cells, the Bax protein resides largely in the cytosol, despite the presence of a typical membrane-anchoring sequence near its C-terminus Wolter et al., 1997) . Following exposure of cells to various apoptotic stimuli, Bax translocates from the cytosol to the membranes of mitochondria, where it inserts as de®ned by resistance to extraction by alkaline or high salt. This insertion process is also accompanied by the exposure of an Nterminal epitope and increased protease sensitivity of the N-terminus of Bax, consistent with the`umbrella' model of insertion mentioned above . Chemical crosslinking studies further suggest that once integrated into membranes, Bax can form dimers and larger oligomers. In addition, one report has suggested that Bax may also undergo a secondary translocation from the outer to the inner membrane . If true, this could potentially provide an explanation for some of the controversy over whether Bcl-2 family proteins (including Bcl-2 and Bcl-X L ) reside in the inner versus outer membrane (Hockenbery et al., 1990; Kharbanda et al., 1997) ; it would also create a scenario reminiscent of the bacterial colicins which similarly translocate to the inner membranes of bacteria, resulting in membrane depolarization and cell death (Cramer et al., 1995) .
It is presently unclear what controls the translocation of Bax from cytosol to mitochondria. When added to isolated mitochondria in the presence of cytosolic extracts, Bax fails to insert into mitochondrial membranes but does so when provided with extracts from apoptotic cells. Deletion of an N-terminal domain from Bax results in constitutive targeting to mitochondria, implying that this domain plays a regulatory function (Goping et al., 1998) . Forced dimerization of Bax can also induce its translocation from cytosol to mitochondrial membranes . Interestingly, unlike Bid, translocation of Bax is not caspase-dependent, though it is somehow prevented by over-expression of Bcl-2 or Bcl-X L .
Addition of Bax to isolated mitochondria induces cytochrome c release through a mechanism that is caspase-independent but suppressible by co-addition of Bcl-X L . The observation that translocation of Bax to mitochondria, membrane insertion, and release of cytochrome c can also take place in the presence of broad-spectrum irreversible caspase inhibitors such as zVAD-fmk, implies that Bcl-2 family proteins possess an Apaf-1-independent mechanism for controlling cell life and death. Bax has also been reported to associate with mitochondria and induce cytochrome c release when expressed in yeast (Manon et al., 1997) which have no caspases. When ectopically expressed in both budding and ®ssion yeast, Bax and Bak confer a lethal phenotype that depends on the presence of the putative pore-forming a5 and a6 helices and which is suppressible by Bcl-2 or Bcl-X L but not by broad-spectrum caspase inhibitors (Ink et al., 1997; JuÈ rgensmeier et al., 1997; Matsuyama et al., 1998) .
More than one way to skin a mitochondrion: Bcl-2 family proteins and the mitochondrial permeability transition pore
The issue of how cytochrome c escapes from mitochondria during apoptosis remains controversial and more than one mechanism may be possible, depending on the particular stimulus and the type of cell involved (Green and Reed, 1998; Reed, 1997a) . The closest structural homolog of Bcl-X L , diphtheria toxin (DT) creates pores that allow the transport of a protein (the ADP-ribosylating A-subunit of the toxin) across lysosomal membranes (Donovan et al., 1982) . Thus, the notion has arisen that Bax might create a channel in the outer membrane which allows cytochrome c leakage into the cytosol, thus departing from its normal location in the space between the inner and outer mitochondrial membranes (IMS).
An alternative mechanism for cytochrome c release envisions a marked change in the permeability of the inner membrane of mitochondria, resulting in osmotic swelling of the organelle and rupture of the outer membrane. During apoptosis induced by myriad insults and stimuli, the electrochemical gradient (DC) across the inner mitochondrial membrane becomes dissipated (reviewed in Petit et al., 1996) . This loss of DC has been attributed to the opening of a large conductance inner membrane channel commonly referred to as the mitochondrial PT pore. Though the structure and biochemical composition of the PT pore remain poorly de®ned, its constituents are thought to include both inner membrane proteins such as the adenine nucleotide translocator (ANT) and outer membranes proteins such as the Voltage-Dependent Anion Channel (VDAC) which operate in concert, presumably at inner and outer membrane contact sites, to create an inner membrane channel with *1.5 kDa diameter (reviewed in Bernardi et al., 1994) . Interestingly, immuno-electron microscopic studies suggest that Bcl-2 is concentrated at these contact sites in the outer membrane of mitochondria (de Jong et al., 1994) . The ANT is the channel protein within the inner membrane thought to be chie¯y responsible for PT (reviewed in Bernardi et al., 1994) . PT can be measured directly in isolated mitochondria based on an increase in their light-absorbance caused by mitochondria swelling in isotonic medium or indirectly by the failure of such mitochondria to take up cationic¯uorescent dyes which rely upon an intact electrochemical gradient (DC) for entry into mitochondria. The opening of this non-selective channel in the inner membrane allows for an equilibration of ions within the matrix and IMS of mitochondria, thus dissipating the electrochemical gradient and uncoupling the respiratory chain (reviewed in Petit et al., 1996) . Secondary consequences of PT pore opening include generation of reactive oxygen species (ROS) and cessation of mitochondrial ATP production. In addition, the volume dysregulation that occurs upon PT pore opening reportedly leads to entry of water into the protein-rich matrix of mitochondria, causing the matrix space to expand. Since the inner membrane with its folded cristae possesses a larger surface area than the outer membrane, this matrix volume expansion can eventually cause the outer membrane to rupture, releasing proteins located within the intermembrane space (IMS) into the cytosol. Recent reports suggest that not only cytochrome c but also other proteins of potential relevance to apoptosis escape from the IMS after treatment of mitochondria with PT-pore inducers, including (a) AIF, a protein that induces apoptosis-like destruction of nuclei ; and (b) caspases-2, -3 and -9, which evidently are sequestered in these organelles under at least some circumstances (Mancini et al., 1998; Susin et al., 1998) .
Bcl-2 family proteins have been reported to associate with PT-pore constituents and regulate the function of this entity in both isolated mitochondria and intact cells. Over-expression of Bcl-2 or Bcl-X L , for example, reportedly confers protection upon mitochondria, making it more dicult for many stimuli to induce PT pore opening, including agents that directly act on these organelles such as cyanide, oligomycin, and atracyloside (Kluck et al., 1997; Marchetti et al., 1996; Shimizu et al., 1996; Susin et al., 1996; Yang et al., 1997) . Conversely, over-expression of the proapoptotic protein Bax in cells or addition of Bax to isolated mitochondria has been demonstrated to induce loss of DC through a caspase-independent mechanism Marzo et al., 1998; Xiang et al., 1996) . Bax also reportedly co-puri®es with the multiprotein PT pore complex from mitochondria and regulates its activity when reconstituted in synthetic liposomes in vitro Marzo et al., 1998) . Moreover, these preparations of partially puri®ed PT pore complexes retain many of the expected functional characteristics when reconstituted in liposomes, including suppression of pore opening by recombinant Bcl-2 protein but not by mutants of Bcl-2 which fail to suppress apoptosis in intact cells Marzo et al., 1998; Zamzami et al., 1998b) . Finally, direct interactions of Bax and the ANT have been reported . Moreover, the ANT agonist atracyloside appears to be incapable of inducing ANT channel opening in the absence of Bax in vitro when reconstituted into liposomes and in isolated mitochondria derived from Bax knock-out mice .
Though accumulating evidence suggests a close collaborative interaction between Bcl-2 family proteins and the PT-pore, it remains controversial whether cytochrome c release occurs as a result of mitochondrial PT or is the cause of it. For example, comparisons of the time-courses of cytochrome c release and mitochondrial DC loss in cells undergoing apoptosis caused by growth factor deprivation or cytotoxic anticancer drugs have provided evidence that cytochrome c release can precede DC loss in at least some types of cells (Bossy-Wetzel et al., 1998; Kluck et al., 1997; Yang et al., 1997) . In addition, evidence has been obtained suggesting that in some circumstances where cytochrome c release appears to precede PT pore opening, caspase activation may be required for the loss of DC but not for the release of cytochrome c (Bossy-Wetzel et al., 1998) . Thus, PT pore opening may be a relatively late event in such cases, occurring as a secondary consequence of Apaf-1-mediated caspase activation. Moreover, apoptosis and cytochrome c release can occur in the absence of any evidence of the mitochondrial swelling predicted to result from PT-pore opening (reviewed in Green and Reed, 1998; Reed, 1997a) . Nevertheless, it is also clear that Bcl-2 can protect against oxidants and other stimuli that directly aect constituents of the PT-pore, thus preventing swelling and rupture of mitochondria (reviewed in Kroemer, 1997; Zamzami et al., 1998a) . Furthermore, indirect evidence has been obtained through use of pharmacological inhibitors of the mitochondrial cyclophilin that regulates the PT pore, supporting the idea of a functional interaction between the PT-pore complex (PTPC) and Bax ± even in settings where Bax induces cytochrome c release from isolated mitochondria without swelling .
How does one reconcile these dierences? One possibility is that both views are correct. Bax, for instance, may be capable of forming large pores in the outer membrane, assisted by interactions with the ANT or other PTPC proteins. Conversely, sustained opening of the ANT, which induces depolarization of the inner membrane, may be aided by Bax ± either through interactions at contact sites where inner and outer membranes abutt or by translocation of Bax to the inner membrane. Bcl-2 and Bcl-X L theoretically could protect mitochondrial membranes by (a) preventing Bax-induced pores in the outer membrane (presumably by blocking Bax's oligomerization with itself or with PTPC proteins); (b) by interfering with Bax's translocation to the inner membrane; or (c) by translocating themselves to the inner membrane and somehow preventing osmotic swelling in their putative capacity as ion-channel proteins. Because these possibilities are not mutually exclusive, the relative contributions of swelling-dependent and swellingindependent release of cytochrome c and other proteins from the IMS may be dictated by a variety of tissue-speci®c dierences in the relative levels of various proteins within the outer and inner membranes of mitochondria. Quite likely, the speci®c death stimulus applied will also feature heavily in determining which mechanism is employed.
Near-death experiences: what de®nes commitment to cell death?
Recent studies have demonstrated that blocking apoptosis induced by growth factor deprivation, staurosporine, or anticancer drugs is not necessarily synonymous with blocking cell death commitment. Caspase-family cell death proteases represent the ultimate eectors of apoptosis. Despite suppressing these proteases with irreversible caspase inhibitors such as zVAD-fmk or similar compounds, and despite preventing all manifestation of apoptosis, cells which have been deprived of growth factors or damaged with chemotherapeutic drugs nevertheless may die through what appears to be delayed necrosis (AmaranteMendes et al., 1998; Bossy-Wetzel et al., 1998; Brunet et al., 1998; Hirsch et al., 1997; McCarthy and Dixit, 1998; Ohta et al., 1997; Vander Heiden et al., 1997) .
This delayed non-apoptotic cell death is preceded by and indeed probably caused by mitochondrial damage which results in release of cytochrome c from these organelles. The loss of cytochrome c from mitochondria not only provides a mechanism for Apaf-1-mediated activation of caspases in the cytosol, but it also interrupts electron transport in the inner membrane, since cytochrome c is responsible for transfer of electrons from complex III to IV in the respiratory chain. Interrupting electron chain-transport has several potential consequences, including causing generation of free-radicals, producing loss of the electrochemical gradient across the inner membrane, and causing ATP depletion (reviewed in Green and Reed, 1998; Reed, 1997a) . Thus, the escape of cytochrome c from mitochondria can induce cell death by two independent routes ± apoptosis (Apaf-1/caspases) and necrosis (electron chain-transport) (Figure 2) .
Interestingly, though caspase inhibitors often fail to prevent mitochondrial damage and commitment to cell death induced by growth factor deprivation and anticancer drugs, clonigenic survival studies indicate that Bcl-2 and Bcl-X L can prevent or reduce cell death under the same circumstances (reviewed in Green and Reed, 1998) . Thus, at least where examined so far, Bcl-2 family proteins appear to govern a cell death Figure 2 Mechanisms of Bcl-2 Action. Bcl-2 may be able to interfere at two points in mitochondria-dependent cell death pathway: (1) preventing cytochrome c release from mitochondria and (2) interfering with Apaf-1. Loss of cytochrome c from mitochondria can result in apoptosis via caspase activation and necrosis due to cessation of electron chain-transport. A feedback loop entails caspase-mediated induction of mitochondrial PT pore opening and recruitment of additional mitochrondria into the process commitment step upstream of caspase activation (Figure 2 ). This does not however exclude the possibility that Bcl-2 also exerts a protective eect downstream of cytochrome c release, as suggested by some recent reports (RosseÂ et al., 1998; Zhivotovsky et al., 1998) . It does, however, provide further evidence that Bcl-2 has caspase-and Apaf-1-independent functions, thus deviating from the CED-9/CED-4/ CED-3 model derived from genetic and biochemical studies of programmed cell death in C. elegans.
Caspases, however, can operate both upstream and downstream of mitochondria, further complicating the issue of de®ning the point or points at which Bcl-2 blocks the cell death pathways. Several studies have provided evidence that active caspases can induce mitochondrial PT pore opening, at least as de®ned by loss of DC Susin et al., 1997) . The mechanisms responsible may entail proteolytic activation of pro-apoptotic proteins such as Bid Luo et al., 1998) or proteolytic removal of the Nterminal BH4 domains from Bcl-2 and Bcl-X L , converting them to killer proteins (Cheng et al., 1997) . These observations imply the existence of a feed-forward mechanism by which cytochrome c release from a few mitochondria can induce caspase activation, thereby recruiting more mitochondria into the process (Figure 2 ).
Can cells be rescued once cytochrome c release has been triggered? In most instances tested thus far, inhibition of caspases has proven insucient to rescue such cells. However, at least one report suggests that some cells can tolerate mitochondrial depletion of cytochrome c, provided caspases are inhibited (Chen et al., 1998b) . This observation implies that release of cytochrome c does not irreversibly commit all cells to death, implying that whatever the mechanism by which cytochrome c escaped from mitochondria, it did not involve irreparable damage to these organelles. In this regard, it warrants noting that the mitochondria of some types of cells are relatively quiescent, with most ATP production coming from anerobic glycolysis. Thus, these cells may tolerate mitochondrial depletion of cytochrome c, at least on a temporary basis, provided caspases are kept under control ± either arti®cially by pharmacological caspase inhibitors or naturally by IAP-family caspase-inhibitory proteins or phosphorylation-mediated inactivation of caspases that operate within the cytochrome c pathway (Cardone et al., 1998; Deveraux et al., 1997) .
Bcl-2-independent pathways for apoptosis While Bcl-2 clearly can govern a cell death commitment step upstream of caspase activation, it has been shown that Bcl-2-independent pathways for caspase activation and apoptosis induction also exist (reviewed in Vaux and Strasser, 1996) . For example, in some (but not all) types of cells, apoptosis triggered by Fas (CD95) and certain members of the Tumor Necrosis Factor (TNF) family of`death receptors' is not blocked by over-expression of Bcl-2 or other anti-apoptotic members of the Bcl-2 family. Fas, and similar TNFfamily receptors that contain`death domains' within their cytosolic tails directly induce caspase activation through ligand-induced recruitment of cytosolic procaspases via interactions with speci®c adaptor proteins (Fadd; Tradd) that bind the death domains of these receptors (Wallach et al., 1997; Yuan, 1997) . Activation of the caspases which interact with TNF-family receptor complexes (e.g., caspases-8 and 10) can trigger a cascade of proteolysis, involving processing and activation of the zymogen forms of other downstream caspases (e.g., caspases-3, 6 and 7) which serve as the ®nal eectors of apoptosis (reviewed in Salvesen and Dixit, 1997b) . In many types of cells, this`death receptor' pathway for apoptosis runs via a Bcl-2-independent pathway, circumventing the participation of mitochondria or other organelles where Bcl-2 and many of its homologs reside as integral membrane proteins.
However, in some cells, Bcl-2 is capable of suppressing Fas-or TNF-induced apoptosis. The basis for this dierence in Bcl-2 sensitivity appears to reside in whether caspase-8 does or does not require a mitochondria-dependent ampli®cation step to achieve sucient activation of downstream eector caspases for apoptosis. For example, addition of recombinant caspase-8 at relatively high concentrations to cytosolic extracts results in activation of downstream caspases as well as apoptosis-like destruction of exogenously added nuclei. In contrast, if lower concentrations of active caspase-8 are added, then downstream caspase activation and nuclear destruction are minimal unless mitochondria are added to the cytosolic extracts (Kuwana et al., 1998) . The in vivo correlate of these experiments involving addition of caspase-8 to cell extracts is found in comparisons of cell lines where Bcl-2 is either eective or ineective as a suppresser of Fasinduced apoptosis (Scadi et al., 1998) . In Bcl-2-suppressible cell lines, only small amounts of caspase-8 activation are induced by Fas. In contrast, in Bcl-2-independent cell lines, abundant amounts of caspase-8 processing and activation are observed. The molecular basis for the dierences in the eciencies of Fasinduced caspase-8 activation remain unde®ned.
Comparisons of the eects of various Bcl-2 family proteins on TNF-or Fas-induced apoptosis also provide an illustration of the molecular diversity of these apoptosis-suppressers. For example, the adenovirus Bcl-2 homolog E1b-19K, which is anchored in the nuclear envelope via associations with nuclear lamins, has been reported to bind Fadd (MORT-1), the adaptor protein required for caspase recruitment to Fas-and TNFR1 (Han et al., 1998) . E1b-19K-mediated sequestration of Fadd therefore presumably prevents it from interacting with Fas and TNFR1 complexes at the plasma membrane. Bcl-2 evidently does not have this capability. Nevertheless, like E1b-19K, the Bcl-2 protein has been reported to have mitochondria-independent functions, including a retention of at least a subset of its apoptosis suppressing activity even when target to the ER, and interactions with a caspase-binding ER protein Bap-31 (Ng et al., 1997; Zhu et al., 1996) .
Conclusions
Bcl-2 family proteins can potentially modulate cell death pathways through multiple mechanisms, including caspase-independent eects on mitochondria and regulation of Apaf-1/CED-4-family proteins. The quantitatively most important of these various mechanisms for controlling cell death most likely varies, depending on the particular type of cell and the cell death stimulus involved. The diversity of antideath mechanisms attributed to Bcl-2, Bcl-X L , and some of their homologs suggests that evolutionary pressure has built several potential functions into these proteins, permitting coordinated regulation of cell life and death decisions. Diverse mechanisms for regulating the levels and functions of Bcl-2 family proteins probably also exist for the purpose of achieving precise control over cell life span regulation in various cellular contexts. Those revealed thus far include transcriptional and post-transcriptional control of gene expression, protein turnover, alterations of protein conformations, protein phosphorylation, proteolytic processing, and protein translocation. Continued attempts to understand the molecular basis of Bcl-2 family protein function and the details of their regulation will reveal strategies for exploiting tissuespeci®c and context-dependent dierences, thus leading to new therapeutic opportunities for the treatment of cancer and other diseases.
